CD8-positive T lymphocyte stimulation via cross-presentation of multiple tumor-associated antigens with viral adjuvants

The phrase "CD8-positive T lymphocyte stimulation through cross-presentation of multiple TAAs combined with viral adjuvants" describes a **biological process** rather than a discrete molecular target. In this context: **Cross-presentation** refers to the ability of certain professional antigen-presenting cells—primarily dendritic cells—to take up exogenous antigens such as tumor-associated antigens (TAAs), process them, and present peptide fragments on MHC class I molecules. This enables the activation ("cross priming") of naive CD8-positive cytotoxic T lymphocytes that would otherwise only recognize peptides derived from endogenous proteins[3][7]. This mechanism is essential for generating immune responses against tumors and viruses that do not directly infect antigen-presenting cells. Combining **multiple TAAs** increases the breadth and potential efficacy against heterogeneous tumors. The use of **viral adjuvants** provides strong inflammatory signals that enhance dendritic cell maturation and promote robust activation rather than tolerance induction. This approach underlies many modern cancer vaccine strategies aiming to elicit potent anti-tumor immunity by harnessing the body's own cytotoxic T cell responses[6]. However, improper regulation can risk breaking self-tolerance and triggering autoimmunity if self-antigens are presented in an activating context[1][4]. Because this entry describes an *immune mechanism* rather than a specific protein or receptor, it does not fit standard definitions for therapeutic targets such as receptors or enzymes. Therefore: The provided name does **not correspond to a canonical molecular target**, but instead refers to an important immunological pathway/process involving several cellular players—most notably conventional type 1 dendritic cells (cDC1), which excel at cross-presentation—and their interaction with CD8+ T lymphocytes in response to exogenous antigenic stimuli including those delivered by viral vectors/adjuvants[6][2]. If you require structured information about individual molecules involved in this pathway—such as "MHC class I," "conventional type 1 dendritic cell," or "CD8-positive T-cell receptor"—please specify which component you wish detailed data for.

Other names

Cross-priming of CD8-positive T cellsCross-presentation-mediated CD8+ T cell activationStimulation of cytotoxic T lymphocytes by cross-presented antigens